

# The Selection and Use of Essential Medicines

---

Report of the WHO Expert Committee, 2011  
(including the 17th WHO Model List of Essential Medicines  
and the 3rd WHO Model List of Essential Medicines for Children)



World Health  
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications. The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about four to six such reports, costs CHF 150.00/US\$ 180.00 (CHF 105.00/US\$ 126.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int); order on line: <http://www.who.int/bookorders>).

# The Selection and Use of Essential Medicines

---

Report of the WHO Expert Committee, 2011  
(including the 17th WHO Model List of Essential Medicines  
and the 3rd WHO Model List of Essential Medicines for Children)

*This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health  
Organization**

WHO Library Cataloguing-in-Publication Data:

The selection and use of essential medicines: report of the WHO Expert Committee, March 2011 (including the 17<sup>th</sup> WHO model list of essential medicines and the 3<sup>rd</sup> WHO model list of essential medicines for children).

(WHO technical report series ; no. 965)

1. Essential drugs - administration and dosage. 2. Drug information services. 3. Drug utilization. 4. Child. I. World Health Organization. II. Series.

ISBN 978 92 4 120965 6

(NLM classification: QV 55 )

ISSN 0512-3054

**© World Health Organization 2012**

All rights reserved. Publications of the World Health Organization are available on the WHO web site ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site ([http://www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of a WHO Expert Committee and does not necessarily represent the decisions or the policies of the World Health Organization.

**Printed in Italy**

# Contents

<b>Executive summary</b>	vii
<b>List of participants of the 18th Expert Committee on the Selection and Use of Essential Medicines</b>	xi
<b>Declaration of interests of Members of the 18th Expert Committee on the Selection and Use of Essential Medicines</b>	xiii
<b>1. Introduction</b>	1
<b>2. Open session</b>	3
<b>3. Review of Report of supplementary session, January 2010: Other antiviral medicines</b>	5
<b>4. General items</b>	9
1: IUPHAR – report on clinical pharmacology	9
2: How to develop a national essential medicines list	9
3: Rational use of medicines – future strategies and directions	10
4: Updated list of missing drug formulations for HIV treatment	10
5: Guidance on the extemporaneous preparation of medicines for children (draft for consultation)	11
6: Review of proposed medical module for inpatient management of severe acute malnutrition with medical complications in children	11
7: Review of application process	12
8: Essential medicines that can be used in neonates	12
<b>5. Applications only for paediatric medicines</b>	13
<b>Section 2: Analgesics, antipyretic medicines, non-steroidal anti-inflammatory medicines (NSAIDs), medicines used to treat gout, and disease-modifying agents in rheumatoid disorders (DMARDs)</b>	13
Section 2.1: Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)	13
Ibuprofen (review) – Children	13
Section 2.2: Opioid analgesics	14
Codeine (deletion) – Children	14
Section 2.4: Disease-modifying agents used in rheumatoid disorders	15
Methotrexate, sulfasalazine, azathioprine, leflunomide, hydroxychloroquine, mycophenolate, and cyclosporine (review) – Children	15
Methotrexate	16
Hydroxychloroquine	20
Leflunomide, sulfasalazine, azathioprine, cyclosporine, mycophenolate	20
<b>Section 4: Antidotes and other substances used in poisonings</b>	21
Section 4.2: Specific	21
Oral iron chelation therapy (review) – Children	21
Oral lead chelation therapy (review) – Children	23
Sodium calcium edetate and penicillamine (review) – Children	23

2,3-dimercapto-1-propanesulfonic acid (DMPS)	23
Penicillamine	24
Sodium calcium edetate and dimercaprol	24
Succimer (new application) – Children	26
<b>Section 6: Anti-infective medicines</b>	27
Neglected tropical diseases (review) – Children	27
Section 6.1: Anthelmintics	27
Section 6.2: Antifilarial medicines	28
Section 6.3: Antischistosomal and antitrepatode medicines	28
Section 6.5: Antiprotozoal medicines	28
Section 6.5.1: Anti-amoebic and anti-giardiasis medicines	28
Section 6.5.2: Antileishmaniasis medicines	29
Section 6.2: Antibacterial medicines	38
Fluoroquinolones (review) – Children	38
<b>Section 8: Antineoplastic agents, immunosuppressives and medicines used in palliative care (review) – Children</b>	39
Section 8.2: Cytotoxic medicines	43
Imatinib (inclusion) – Children and adolescents	43
Section 8.4: Medicines used in palliative care	44
<b>Section 10: Medicines affecting the blood</b>	44
Section 10.2: Medicines affecting coagulation	44
Antithrombotic (review) – Children	44
<b>Section 15: Disinfectants and antiseptics</b>	46
Chlorhexidine (change of formulation) – Children	46
<b>Section 16: Diuretics</b>	48
Mannitol (review) – Children	48
Spironolactone (review) – Children	48
<b>Section 17: Gastrointestinal medicines</b>	49
Section 17.5: Medicines used in diarrhoea	49
Section 17.5.2: Medicines for diarrhoea in children	49
Zinc sulfate (new formulation) – Children	49
<b>Section 18: Hormones</b>	50
Section 18.5: Insulins and other antidiabetic agents	50
Review of the use of oral hypoglycaemic agents in children (review) – Children	50
<b>6. Applications for the 17th Model List and the 3rd EMLc</b>	53
<b>Section 1: Anaesthetics</b>	53
Section 1.1: General anaesthetics and oxygen	55
Ether (re-instatement)	55
Promethazine (deletion) – Adults and children	56
Propofol (inclusion)	57
Section 1.3: Preoperative medication and sedation for short-term procedures	58
Midazolam (inclusion)	58
<b>Section 4: Antidotes and other substances used in poisonings</b>	59
Section 4.2: Specific	59
DL-methionine (deletion)	59
<b>Section 6: Anti-infective medicines</b>	60
Section 6.2: Antibacterial medicines	60

Section 6.2.2:	Other antibacterial medicines	60
	Gatifloxacin (inclusion)	60
	Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim (new formulation)	61
	Sulfamethoxazole + trimethoprim (new formulation)	62
Section 6.4:	Antiviral medicines	63
Section 6.4.2:	Antiretroviral medicines	63
Section 6.4.2.2:	Non-nucleoside reverse transcriptase inhibitors	63
	Etravirine (inclusion)	63
Section 6.4.2.3:	Protease inhibitors	64
	Darunavir (inclusion)	64
Section 6.4.2.4:	Integrase inhibitors (new section heading)	65
	Raltegravir (inclusion)	65
Section 6.5:	Antiprotozoal medicines	65
Section 6.5.2:	Antileishmaniasis medicines	65
	Miltefosine (inclusion) – Adults and children	65
Section 6.5.3:	Antimalarial medicines	67
	Artesunate + amodiaquine fixed-dose combination (inclusion) – Adults and children	67
	Dihydroartemisinin + piperaquine (inclusion) – Adults and children	69
	Pyronaridine + artesunate fixed-dose combination (inclusion) – Adults and children	70
<b>Section 8:</b>	<b>Antineoplastic agents, immunosuppressives, and medicines used in palliative care</b>	71
Section 8.2:	Cytotoxic medicines	71
	Paclitaxel (inclusion); Docetaxel (inclusion)	71
<b>Section 10:</b>	<b>Medicines affecting the blood</b>	72
Section 10.2:	Medicines affecting coagulation	72
	Tranexamic acid (inclusion)	72
<b>Section 12:</b>	<b>Cardiovascular medicines</b>	74
	Bisoprolol (inclusion) – square box	74
<b>Section 13:</b>	<b>Dermatological medicines (topical)</b>	76
	Dermatological medicines (review) – Adults and children	76
<b>Section 17:</b>	<b>Gastrointestinal medicines</b>	77
Section 17.1:	Antacids and other anti-ulcer medicines	77
	Aluminium hydroxide (deletion)	77
	Magnesium hydroxide (deletion)	77
	Review of treatment of <i>Helicobacter pylori</i> in adults and children	78
Section 17.5:	Medicines used in diarrhoea	80
Section 17.5.3:	Antidiarrhoeal (symptomatic) medicines in adults	80
	Codeine (deletion); Loperamide (inclusion)	80
<b>Section 18:</b>	<b>Hormones, other endocrine medicines and contraceptives</b>	81
Section 18.4:	Estrogens	81
	Ethinylestradiol (deletion)	81
Section 18.7:	Progestogens	81
	Norethisterone and medroxyprogesterone acetate (deletion)	81
Section 18.5:	Insulins and other antidiabetic agents	83
	Glucagon (inclusion)	83
	Review of the evidence comparing insulin (human or animal) with analogue insulins (review)	84

<b>Section 22: Oxytocics and anti-oxytocics</b>	85
Section 22.1: Oxytocics	85
Misoprostol (new formulation)	85
Oxytocin (change of formulation)	88
<b>Section 24: Psychotherapeutic medicines</b>	89
Psychotherapeutic medicines (review of section headings)	89
<b>Section 25: Medicines acting on the respiratory tract</b>	90
Section 25.1: Anti-asthmatic medicines and medicines for chronic obstructive pulmonary disease	90
Salbutamol (deletion)	90
New section: Haemaglobinopathies	91
Hydroxycarbamide (inclusion)	91
<b>7. Summary of recommendations</b>	93
17th WHO Model List of Essential Medicines	93
Additions to Model List	93
Deletions from Model List	95
Changes to sections	96
Amended dosage strength and form	97
Rejected applications	97
3rd Essential Medicines List for children	98
Additions to EMLC	98
Deletions from EMLC	99
Changes to sections	100
Amended dosage strength and form	101
Rejected medicines	101
Recommendations for reviews	102
Medicines marked for consideration of deletion at the next meeting	103
Missing essential medicines	103
<b>Annex 1: 17th WHO Model List of Essential Medicines</b>	105
<b>Annex 2: 3rd WHO Model List of Essential Medicines for Children</b>	149
Appendix: Essential medicines that can be used in neonates	182
<b>Annex 3: The Anatomical Therapeutic Chemical (ATC) Classification System</b>	185
<b>Annex 4: Alphabetical list of essential medicines (with ATC)</b>	

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>